TUTOR Phase 1 Trial Combines Stereotactic Radiosurgery with Triple HER2-Targeted Therapy for Brain Metastases
核心洞察
The TUTOR Phase 1 trial is evaluating the combination of stereotactic radiosurgery with tucatinib, trastuzumab, and capecitabine for treating brain metastases (搜索) from HER2-positive breast cancer (搜索).
The multicenter clinical trial is currently recruiting patients at Miami Cancer Institute (搜索) under the leadership of Dr. Manmeet Ahluwalia.
The study protocol has been published in BMC Cancer, representing a novel approach to managing brain metastases (搜索) in HER2-positive breast cancer (搜索) patients.
The TUTOR Phase 1 clinical trial is investigating a novel combination approach for treating brain metastases (搜索) from HER2-positive breast cancer (搜索), combining stereotactic radiosurgery (SRS) with a triple-drug targeted therapy regimen consisting of tucatinib, trastuzumab, and capecitabine.
Trial Design and Objectives
The multicenter Phase 1 trial is designed to evaluate how effectively brain metastases (搜索) associated with HER2-positive breast cancer (搜索) can be controlled using stereotactic radiosurgery when combined with the three therapeutic agents. The study is currently recruiting patients at Miami Cancer Institute (搜索), Baptist Health South Florida Foundation (搜索).
Dr. Manmeet Ahluwalia, MD, MBA, FASCO, is leading this clinical investigation, which represents a comprehensive approach to managing brain metastases (搜索) in this patient population. The trial protocol has been published in BMC Cancer, providing detailed methodology for this innovative treatment combination.
Treatment Approach
The TUTOR trial combines two distinct therapeutic modalities: precision radiation therapy through stereotactic radiosurgery and systemic targeted therapy. The radiation component utilizes SRS, a highly focused radiation technique that delivers precise doses to brain metastases (搜索) while minimizing exposure to surrounding healthy tissue.
The systemic therapy component consists of three agents specifically targeting HER2-positive breast cancer (搜索):
- Tucatinib, a selective HER2 tyrosine kinase inhibitor
- Trastuzumab, a monoclonal antibody targeting HER2
- Capecitabine, an oral chemotherapy agent
Research Team and Publication
The study protocol was developed by a multidisciplinary team of researchers and clinicians. According to Mainak Bardhan, Doctoral Researcher at Howard Hughes Medical Institute-University of Miami Miller School of Medicine, the publication represents a collaborative effort involving multiple specialists in oncology and radiation therapy.
Zouina Sarfraz, Postdoctoral Research Fellow in Oncology at the Miami Cancer Institute (搜索), described the publication as "a much-needed end to a wonderful 2025" and expressed gratitude for Dr. Ahluwalia's leadership and mentorship in the project.
Clinical Significance
Brain metastases (搜索) represent a significant challenge in HER2-positive breast cancer (搜索) management, and the TUTOR trial addresses this unmet medical need through a combination approach. By integrating stereotactic radiosurgery with targeted systemic therapy, the trial aims to optimize both local control of brain metastases and systemic disease management.
The publication of the study protocol in BMC Cancer provides the scientific community with detailed methodology for this treatment approach, potentially informing future clinical practice and research directions in neuro-oncology and breast cancer care.